Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly?

Página do item simplificado
dc.contributor.authorJones, Ronald N.
dc.contributor.authorSader, Helio S.
dc.contributor.institutionJMI Labs
dc.contributor.institutionTufts Univ
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T12:41:22Z
dc.date.available2016-01-24T12:41:22Z
dc.date.issued2006-08-01
dc.description.abstractThe spectrum and potency of cefdinir, an orally administered cephalosporin, was reevaluated for the uncomplicated skin and soft tissue infection (uSSTI) indication using contemporary isolates from 2004 to 2005. Cefdinir continues to have high rates of susceptibility against methicillin-susceptible staphylococci (100.0%), beta-hemolytic streptococci (groups A and 13; 100.0%), viridans group streptococci (88.9%), Escherichia coli (93.2%), and Klebsiella pneumoniae (90.0%). No diminished activity was detected since the last evaluation (19972002 isolates), and cefdinir remains significantly more potent (4- to 16-fold) than cephalexin, even when using surrogate agents of cephalexin susceptibility that were suspect for over estimating true clinical utility. Activity greater than cephalexin (4-fold) was also noted for cefdinir against community-associated methicillin-resistant Staphylococcus aureus isolates. Cefdinir should be considered as a viable option for the therapy uSSTI caused by indicated species. (c) 2006 Elsevier Inc. All rights reserved.en
dc.description.affiliationJMI Labs, N Liberty, IA 52317 USA
dc.description.affiliationTufts Univ, Sch Med, Boston, MA 02111 USA
dc.description.affiliationUniversidade Federal de São Paulo, Div Infect Dis, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Div Infect Dis, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent351-356
dc.identifierhttp://dx.doi.org/10.1016/j.diagmicrobio.2006.04.015
dc.identifier.citationDiagnostic Microbiology and Infectious Disease. New York: Elsevier B.V., v. 55, n. 4, p. 351-356, 2006.
dc.identifier.doi10.1016/j.diagmicrobio.2006.04.015
dc.identifier.issn0732-8893
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/29068
dc.identifier.wosWOS:000239827300016
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofDiagnostic Microbiology and Infectious Disease
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.subjectcefdiniren
dc.subjectcephalexinen
dc.subjectuSSTIen
dc.subjectCA-MRSAen
dc.subjectresistanceen
dc.subjectreevaluationen
dc.subjectcephalosporinsen
dc.titleUpdate on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly?en
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral